AZN•benzinga•
AstraZeneca Highlights Significant Gains Across Three Major Cancer Trials At ASCO
Summary
AstraZeneca reports major survival benefits in breast and gastric cancer trials with Enhertu, Imfinzi, and camizestrant at ASCO 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga